If you need more lookups,
subscriptions start at $34 USD/month.
Andy Parker Location
France
Andy Parker Work
President and Chief Executive Officer @ (September 2019 - Present)
Board Member @ Eclosion2 SA (July 2016 - Present)
Scientific Advisor @ Foundation Eclosion (July 2016 - December 2020)
Board Member @ PEPTIDE THERAPEUTICS FOUNDATION (October 2016 - October 2019)
CSO and EVP, Head of Research and External Innovation @ (July 2016 - August 2019)
General Partner and Scientific Director @ Eclosion2 (January 2014 - June 2016)
Vice President, Head of Exploratory Projects @ (January 2011 - December 2013)
Vice President of Research @ Opsona Therapeutics (November 2008 - December 2010)
Associate Director, Respiratory and Inflammation Research @ (January 1998 - October 2008)
Team Leader @ (October 1995 - December 1997)
Andy Parker Education
University of Warwick - Warwick Business School
MBA
2011-2013
The Johns Hopkins University School of Medicine
Post Doctoral Fellow (Molecular & Cell Biology)
1992-1996
National Institute for Medical Research
Ph.D. (Molecular & Cell Biology)
1988-1991
University of Surrey
B.Sc (Microbiology)
1984-1988
Andy Parker Skills
Biochemistry
Biotechnology
CRO
Cancer
Cell
Clinical Development
Clinical Trials
Drug Development
Drug Discovery
In Vitro
Life Sciences
Lifesciences
Medicinal Chemistry
Oncology
Pharmaceutical Industry
Pharmacology
R&D
Technology Transfer
Training
Healthcare
Team Leadership
Project Management
Business Strategy
Research
Andy Parker Summary
Andy Parker, based in France, is currently a President and Chief Executive Officer at Step Pharma. Andy Parker brings experience from previous roles at Eclosion2 SA, Foundation Eclosion, PEPTIDE THERAPEUTICS FOUNDATION and Zealand Pharma A/S. Andy Parker holds a 2011 - 2013 MBA @ University of Warwick - Warwick Business School. With a robust skill set that includes Biochemistry, Biotechnology, CRO, Cancer, Cell and more. Andy Parker has 1 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Andy Parker?
Find contact details for 700 million professionals.